NO20100596L - Kinolonanaloger og fremgangsmater - Google Patents

Kinolonanaloger og fremgangsmater

Info

Publication number
NO20100596L
NO20100596L NO20100596A NO20100596A NO20100596L NO 20100596 L NO20100596 L NO 20100596L NO 20100596 A NO20100596 A NO 20100596A NO 20100596 A NO20100596 A NO 20100596A NO 20100596 L NO20100596 L NO 20100596L
Authority
NO
Norway
Prior art keywords
methods
quinolone analogs
present
compounds
quinolone
Prior art date
Application number
NO20100596A
Other languages
English (en)
Inventor
Jeffrey P Whitten
Michael K Schwaebe
Fabrice Pierre
Johnny Yasuo Nagasawa
Mustapha Haddach
Levan Darjania
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of NO20100596L publication Critical patent/NO20100596L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16Peri-condensed systems

Abstract

Foreliggende oppfinnelse tilveiebringer nye kinolonforbindelser og farmasøytiskpreparat derav som kan hemme celleproliferasjonen og/eller fremkalle celle-apoptose. Foreliggende oppfinnelse tilveiebringer også metoder for fremstilling av slike forbindelser og preparater og metoder for anvendelse derav.
NO20100596A 2007-10-05 2010-04-26 Kinolonanaloger og fremgangsmater NO20100596L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97804207P 2007-10-05 2007-10-05
US3868108P 2008-03-21 2008-03-21
US4593308P 2008-04-17 2008-04-17
PCT/US2008/078859 WO2009046383A1 (en) 2007-10-05 2008-10-03 Quinolone analogs and methods related thereto

Publications (1)

Publication Number Publication Date
NO20100596L true NO20100596L (no) 2010-06-10

Family

ID=40523786

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20100596A NO20100596L (no) 2007-10-05 2010-04-26 Kinolonanaloger og fremgangsmater

Country Status (19)

Country Link
US (2) US7928100B2 (no)
EP (2) EP2214491B1 (no)
JP (2) JP5824213B2 (no)
KR (2) KR101682867B1 (no)
CN (1) CN101888780B (no)
AU (1) AU2008308485B2 (no)
BR (1) BRPI0817806A2 (no)
CA (1) CA2701630C (no)
DK (1) DK3092901T3 (no)
ES (2) ES2791305T3 (no)
HK (1) HK1150728A1 (no)
IL (2) IL204844A (no)
MX (1) MX2010003685A (no)
NO (1) NO20100596L (no)
NZ (1) NZ584892A (no)
PL (2) PL2214491T3 (no)
PT (2) PT3092901T (no)
RU (1) RU2549895C2 (no)
WO (1) WO2009046383A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008131134A1 (en) * 2007-04-17 2008-10-30 Cylene Pharmaceuticals, Inc. Hydrazide compounds and uses thereof
PT3092901T (pt) * 2007-10-05 2020-05-21 Senhwa Biosciences Inc Análogos de quinolona e respetivos métodos relacionados
AR077974A1 (es) 2009-08-28 2011-10-05 Takeda Pharmaceutical Compuestos de hexahidrooxazinopterina para uso como inhibidores de mtor
CN102574789B (zh) * 2009-09-21 2014-12-10 凯莫森特里克斯股份有限公司 吡咯烷酮甲酰胺衍生物作为趋化素-r(chemr23)调节剂
CA2827770A1 (en) 2011-02-25 2012-11-01 Takeda Pharmaceutical Company Limited N-substituted oxazinopteridines and oxazinopteridinones
WO2012123938A1 (en) 2011-03-17 2012-09-20 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
GB201206384D0 (en) * 2012-04-11 2012-05-23 Redx Pharma Ltd Antibacterial drug derivatives
CN104177379B (zh) * 2013-05-22 2016-12-28 中国科学院上海药物研究所 一种喹诺酮类化合物或其立体化学异构体、包含该化合物的药物组合物及其用途
ES2754207T3 (es) 2013-11-28 2020-04-16 Tel Hashomer Medical Res Infrastructure & Services Ltd Inhibidores de la ARN polimerasa I y usos de los mismos
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
LT3140305T (lt) 2014-05-09 2018-09-10 Pimera, Inc. Naujos kompozicijos, panaudojimas ir jų gamybos būdai
WO2017087235A1 (en) * 2015-11-20 2017-05-26 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
AU2015417382A1 (en) * 2015-12-14 2018-06-14 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
TWI765848B (zh) * 2015-12-14 2022-06-01 生華生物科技股份有限公司 喹諾酮類似物及其鹽的結晶形式
US9957282B2 (en) 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
JP2020512975A (ja) 2017-03-28 2020-04-30 ピメラ,インク. Pol1阻害剤の新規な結晶形態
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
TW202000195A (zh) 2018-02-15 2020-01-01 生華生物科技股份有限公司 喹啉酮類似物及其鹽、組合物及其使用方法
WO2020051342A1 (en) * 2018-09-06 2020-03-12 Cornell University Methods for treating metastatic disease using ribosome biogenesis inhibitor cx 5461
CA3151116A1 (en) * 2019-08-14 2021-02-18 Hshiou-Ting Liu Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
EP4013421A4 (en) * 2019-08-14 2023-08-23 Senhwa Biosciences, Inc. TETRACYCLIC COMPOUNDS AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE
JP2020189888A (ja) * 2020-08-28 2020-11-26 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形
CN114573604A (zh) * 2020-12-01 2022-06-03 中国科学院上海药物研究所 一类基于喹诺酮的化合物、其制备方法、包含其的药物组合物及其用途
EP4308105A1 (en) 2021-03-19 2024-01-24 Trained Therapeutix Discovery, Inc. Compounds for regulating trained immunity, and their methods of use
CN114409681A (zh) * 2022-03-18 2022-04-29 信义核新(北京)生物科技有限公司 用于治疗dna损伤修复缺陷肿瘤的喹诺酮类似物及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) * 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EG20543A (en) * 1992-10-30 1999-07-31 Procter & Gamble Process for preparing of novel antimicrobial -5- (n-heterosubstituted amino) quinolones
EP1165508B1 (en) 1999-04-07 2004-06-23 The University of Virginia Patent Foundation Anticancer calcium channel blockers
JP2005511743A (ja) 2001-12-13 2005-04-28 ウォックハート・リミテッド 新世代の三重標的化したキラルな広域スペクトラム抗菌性の7位置換ピペリジノ−キノロンカルボン酸誘導体、その調製方法、組成物、および医薬としての使用
US6900224B2 (en) * 2002-07-31 2005-05-31 The Procter & Gamble Company Antimicrobial quinolones, their compositions and uses
CN1997642B (zh) * 2003-09-22 2012-06-13 詹森药业有限公司 7-氨基亚烷基-杂环喹诺酮类和萘啶酮类
WO2006034113A2 (en) * 2004-09-17 2006-03-30 Cylene Pharmaceuticals, Inc. Quinolone analogs as cell proliferation inhibitors
WO2007019295A1 (en) * 2005-08-05 2007-02-15 Cylene Pharmaceuticals, Inc. Methods of preparing quinolone analogs
CA2619663A1 (en) * 2005-08-19 2007-02-22 Cylene Pharmaceuticals, Inc. Human ribosomal dna(rdna) and ribosomal rna (rrna) nucleic acids and uses thereof
AR057555A1 (es) * 2005-10-27 2007-12-05 Merck Frosst Canada Ltd Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
US20090291437A1 (en) * 2005-11-02 2009-11-26 O'brien Sean Methods for targeting quadruplex sequences
EP2023720A4 (en) 2006-05-17 2009-06-10 Cylene Pharmaceuticals Inc TETRACYCLIC IMIDAZOLE ANALOGS
WO2007146831A2 (en) * 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
US20110112086A1 (en) 2006-06-08 2011-05-12 Cylene Pharmaceuticals, Inc. Pyridinone analogs
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
WO2008131134A1 (en) * 2007-04-17 2008-10-30 Cylene Pharmaceuticals, Inc. Hydrazide compounds and uses thereof
PT3092901T (pt) 2007-10-05 2020-05-21 Senhwa Biosciences Inc Análogos de quinolona e respetivos métodos relacionados

Also Published As

Publication number Publication date
RU2010117225A (ru) 2011-11-10
AU2008308485B2 (en) 2014-08-07
JP2014159474A (ja) 2014-09-04
KR20100064392A (ko) 2010-06-14
WO2009046383A1 (en) 2009-04-09
KR20160020578A (ko) 2016-02-23
EP2214491A4 (en) 2010-11-10
ES2791305T3 (es) 2020-11-03
IL204844A0 (en) 2010-11-30
EP2214491A1 (en) 2010-08-11
DK3092901T3 (da) 2020-05-18
CA2701630C (en) 2016-10-25
PL2214491T3 (pl) 2016-11-30
EP3092901A1 (en) 2016-11-16
US7928100B2 (en) 2011-04-19
KR101601332B1 (ko) 2016-03-08
CN101888780A (zh) 2010-11-17
IL249906B (en) 2020-10-29
JP5824213B2 (ja) 2015-11-25
PT2214491T (pt) 2016-10-25
US8853234B2 (en) 2014-10-07
CA2701630A1 (en) 2009-04-09
IL204844A (en) 2017-01-31
EP2214491B1 (en) 2016-07-13
ES2582662T3 (es) 2016-09-14
RU2549895C2 (ru) 2015-05-10
EP3092901B1 (en) 2020-04-29
PL3092901T3 (pl) 2020-10-19
IL249906A0 (en) 2017-03-30
PT3092901T (pt) 2020-05-21
AU2008308485A1 (en) 2009-04-09
JP2010540663A (ja) 2010-12-24
KR101682867B1 (ko) 2016-12-05
US20110218184A1 (en) 2011-09-08
HK1150728A1 (en) 2012-01-13
US20090093455A1 (en) 2009-04-09
BRPI0817806A2 (pt) 2014-10-07
NZ584892A (en) 2012-06-29
MX2010003685A (es) 2010-06-02
CN101888780B (zh) 2014-08-13

Similar Documents

Publication Publication Date Title
NO20100596L (no) Kinolonanaloger og fremgangsmater
PH12017500660A1 (en) Novel compositions, uses and methods for making them
CY1122330T1 (el) Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
CO2017011151A2 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CY1118859T1 (el) 6-αλκινυλο-πυριδινες ως μιμητες smac
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
BR112012008385A2 (pt) inibidores de p13 cinase e uso dos mesmos.
CO2017011152A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx / ca.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
TR201900274T4 (tr) Geliştirilmiş adenovirüs formülasyonları.
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX351165B (es) Antagonistas de trpv1.
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
NO20090596L (no) Antivirale fosfinatforbindelser
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
CL2014001060A1 (es) Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades.
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
CL2011002965A1 (es) Compuestos derivados de piperidinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso de dichos compuestos para el tratamiento y/o profilaxis de trastornos cardiovasculares, tromboembolicos y/o tumores.
GT201500143A (es) Composiciones que comprenden vortioxetina y donepezilo campo tecnico

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application